9th Jan 2019 09:26
LONDON (Alliance News) - Silence Therapeutics PLC said Wednesday Chief Financial Officer David Ellam has resigned from the serious disease treatment firm with immediate effect.
Ellam - CFO since 2016 - will be replaced on an interim basis by Head of Financial Planning & Analysis Rob Quinn until a new permanent appointment is made.
"On behalf of the board I would like to thank David for his contribution to Silence," Silence Therapeutics Chief Executive Officer David Horn Solomon said.
"He has played an important role in building the business and placing Silence Therapeutics in a strong position to continue the development of its product pipeline in the RNAi medicines space. We wish David every success for the future", Solomon added.
Shares in Silence Therapeutics were 2.3% higher at 54.40 pence on Wednesday.
Related Shares:
SLN.L